Nadim Ajami

Executive Director

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Year:

2026

Year:

2026

Lower gastrointestinal graft-versus-host disease (LGI-GVHD) carries morbidity and mortality for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), with critical contributions from the intestinal microbiome. In a retrospective cohort of metagenomic sequencing of allo-HSCT patient stool (n = 90), we found that a reduction in specific Parabacteroides and Bacteroides species around the time of engraftment contributes to LGI-GVHD risk. Given the known diverse carbohydrate degrading functionality of these bacteria, we investigated gene abundances for Carbohydrate-Active enZyme (CAZyme) and found that Parabacteroides merdae, Parabacteroides distasonis and Bacteroides ovatus abundances were significantly correlated with CAZymes in patients who did not develop LGI-GVHD compared to those who did. The specific gene abundances of xylosidase, which contribute to the degradation of xylose-containing polysaccharides, were significantly associated with reduced risk of LGI-GVHD. Together, these findings show the importance of carbohydrate degrading functionality of putative beneficial bacteria in mediating risk of LGI-GVHD.

Year:

2026

The gut microbiome has emerged as a key regulator of response to cancer immunotherapy. However, a better understanding of the underlying mechanisms by which the microbiome influences immunotherapy is needed to identify strategies to optimize outcomes. To this end, we developed a mathematical model to obtain insights into the effect of the microbiome on the immune system and immunotherapy response. This model was based on (i) gut microbiome data derived from preclinical studies, (ii) mathematical modeling of the antitumor immune response, (iii) association analysis of microbiome profiles with model-predicted immune profiles, and (iv) statistical models that correlate model parameters with the microbiome. The model was used to investigate the complexity of murine and human studies on microbiome modulation. Comparison of model predictions with experimental observations of tumor response in the training and test datasets supported the hypothesis that two model parameters, the activation and killing rate constants of immune cells, are the most influential in tumor progression and are potentially affected by microbiome composition. Evaluation of the associations between the gut microbiome and immune profile indicated that the components and structure of the gut microbiome affect the activation and killing rate of adaptive and innate immune cells. Overall, this study contributes to a deeper understanding of microbiome–cancer interactions and offers a framework for understanding how microbiome interactions influence cancer treatment outcomes. Significance: Integration of mathematical modeling and microbiome data reveals how gut microbiome components impact immune response, providing insights to optimize immunotherapy strategies. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI.

Year:

2025

Background/Objectives: Immune checkpoint blockade (ICB) therapies have significantly improved outcomes in metastatic melanoma. However, immune-related adverse events (irAEs) and persistent chronic toxicities (CTs) among this emerging survivor population likely influence different facets of quality of life. This study characterized CT, patient-reported outcomes (PROs), diet, physical activity and gut microbiome features in a cohort of long-term survivors with a history of ICB-treated metastatic melanoma. Methods: Forty-eight patients with a history of metastatic melanoma who initiated ICB treatment at least 3 years earlier and were not currently on treatment were prospectively enrolled from a melanoma survivorship clinic. Participants completed screening questionnaires for depression, anxiety, diet and physical activity. The gut microbiome was characterized via metagenomic sequencing in a subsample (n = 39). Patients’ clinicopathological characteristics and experience of irAEs (during treatment) and CT (persisting >6 months after completion of therapy) were extracted retrospectively from the medical record. Results: In the overall cohort, 60% were experiencing CT, while 16% and 20% reported clinically relevant levels of depression and anxiety symptoms, respectively. We observed significant differences in overall gut microbiome composition between survivors with and without CT (p = 0.02). Consumption of fruit and vegetables was inversely associated with anxiety (ρ = 0.3, p = 0.038). Added sugar consumption was correlated with the severity of experienced symptoms (ρ = 0.4, p = 0.003), with pronounced associations across the spectrum of symptoms, including pain, fatigue and shortness of breath (p < 0.05). Conclusions: These results suggest that CT is experienced by a substantial proportion of ICB-treated metastatic melanoma survivors. Patients experiencing CT also showed distinct microbiome features. However, additional research in prospective settings is needed to confirm these hypotheses.

Year:

2025

Immune cell analysis by BMI and sex. A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis of the Gide cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor.

Year:

2025

Integrated gene set enrichment analysis of subgroups by body mass index BMI. This figure compares gene expression between overweight/obese (OW/OB) and normal (NL) BMI patients with metastatic melanoma across subgroups by sex, cohort, and tissue site. Supplementary Figure 2 presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients by subgroups. Red indicates upregulation in OW/OB verse NL.

Year:

2025

Integrated gene set enrichment analysis by body mass index (BMI) with correction for S phase. This figure presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients. Red indicates upregulation in OW/OB verse NL. The far left column is all patients, and then, an analysis controlling for sex, cohort, and tissue site is shown in the 3 columns to the right.

Year:

2025

Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 x IQR. The red dots represent OW/OB patients and the blue dots represent NL patients by BMI. This is a subgroup analysis of Figure 5C.

Year:

2025

Direct metabolite measurements from a subset of The Cancer Genome Atlas (TCGA) cohort. Comparison of additional tricarboxylic acid cycle metabolites measured by liquid chromatography/mass spectrometry between metastatic melanoma tumors from overweight/obese (OW/OB) patients by body mass index (BMI) verse normal (NL) BMI from The Cancer Genome Atlas (TCGA). Lines represent mean +/- SEM; each dot represents a single tumor.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (66)

Georgina V. Long

University of Sydney

AUSTRALIA
View details

Guido Kroemer

-

FRANCE
View details

Lauren Haydu

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Carrie Daniel

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

David J. Tweardy

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Richard Champlin

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Valerio Iebba

Assistant Professor

University of Trieste

ITALY
View details

Didier Hocquet

Full Prof. - Hospital Practitioner

Hôpital Jean Minjoz

FRANCE
View details

olivier adotevi

INSERM UMR 1098 RIGHT

FRANCE
View details

matthew ross

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Cheuk Hong Leung

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mathieu Chevalier

Assistant Professor

INSERM U976, Institut de Recherche Saint-Louis, Université de Paris

FRANCE
View details

Chantale Bernatchez

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ralph J. DeBerardinis

University of Texas Southwestern Medical Center

UNITED STATES
View details

Kristi Hoffman

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Markus Maeurer

University of Mainz

GERMANY
View details

Jennifer L. McQuade

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jun Li

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Alexander M. Menzies

University of Sydney

AUSTRALIA
View details

Julia Thorn-Seshold

Group Leader

Technische Universität Dresden

GERMANY
View details

Xiaotao Zhang

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Theodore S. Nowicki

University of California

UNITED STATES
View details

Greg M. Delgoffe

-

UNITED STATES
View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES
View details

Simon Rothenfusser

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

laurence ZITVOGEL

Université Paris-Saclay

FRANCE
View details

Vashisht Yennu Nanda

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nicola Segata

Group Leader

University of Trento

ITALY
View details

Genevieve Boland

Chair of Surgery

Medical College of Wisconsin

UNITED STATES
View details

Junya Fujimoto

Professor and Chair

Hiroshima University Hospital

JAPAN
View details

John Thompson

Clinical Professor

University of Sydney

AUSTRALIA
View details

Triantafyllos Stylianopoulos

Associate Professor

-

CYPRUS
View details

Grant Fischer

Assistant Professor of Molecular Genetic Pathology (Tenure Track)

University of North Carolina at Chapel Hill

UNITED STATES
View details

Alexandra Ikeguchi

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sebastian Kobold

University Hospital

GERMANY
View details

I. Jolanda M. de Vries

Department head

Radboudumc

NETHERLANDS
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wen-Bin Tsai

Senior Staff Scientist

Baylor College of Medicine

UNITED STATES
View details

Elizabeth Burton

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael White

Assistant Professor

-

UNITED STATES
View details

Isabella C Glitza Oliva

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Aditya Mishra

University of Georgia

UNITED STATES
View details

Lisa Derosa

Assistant Professor

Université Paris-Saclay

FRANCE
View details

Ryan Sullivan

Harvard University

UNITED STATES
View details

Christine Spencer

Parker Institute for Cancer Immunotherapy

UNITED STATES
View details

Robert Jenq

Professor

City Of Hope National Medical Center

UNITED STATES
View details

Dirk Schadendorf

University Hospital Essen

GERMANY
View details

Han Liang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Seyed Javad Moghaddam

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Silvia Formenti

Cornell University

UNITED STATES
View details

James Wilmott

Associate Professor

The University of Sydney Library

AUSTRALIA
View details

Sophie Caillat-Zucman

Professeur

Université Paris Diderot

FRANCE
View details

yana najjar

University of Pittsburgh

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Julie Densmore

Parker Institute for Cancer Immunotherapy

UNITED STATES
View details

Christine Peterson

Associate Professor

Rice University

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Humam Kadara

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details

Joseph Petrosino

Department Chair

Baylor College of Medicine

UNITED STATES
View details

Nagireddy Putluri

Professor (Tenured)

Baylor College of Medicine

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Weiyi Peng

Director

University of Houston

UNITED STATES
View details